Phase II findings have shown a substantial improvement in overall survival with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study.
glioblastoma immunotherapy
Patrick Y. Wen, MD
Phase II findings have shown a substantial improvement in overall survival (OS) with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study, according to data presented at the 2015 Society for Neuro-Oncology Annual Meeting.
The subgroup of patients showed substantial improvement in overall survival (OS) with the immunotherapy due to an immune response to ICT-107 by enzyme-linked immunospot (ELISPOT). In the group of responders from the phase II study, the median OS was 23.1 months compared with 13.7 months in non-responders (P= .0674). For responders, OS was extended by 52% compared with 29% in non-responders (P= .0615). Progression-free survival (PFS) was extended by 41% versus 15% in non-responders (P= .0259).
“ICT 107 is a dendritic cell peptide vaccine that has shown promising results in a randomized phase II study in patients with newly-diagnosed glioblastomas and was very well-tolerated,” said Patrick Y. Wen, MD, director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, toldTargeted Oncology. “If the recently launched phase III study confirms these findings, it will bring a much-needed treatment to our patients.
In the study, 124 patients were randomized at a 2:1 ratio to receive ICT-107 or matching control (unincubated dendritic cells), 77% of which were HLA-A2+. Treatment arm patients (n = 81) received 4 induction doses of ICT-107 after chemoradiation, with subsequent maintenance doses until progression.
The overall median OS with ICT-107 was 18.3 versus 16.7 months for control (HR, 0.89,P= .643). Median PFS was 11.2 months with ICT-107, as opposed to 9.0 months in the control arm (HR, 0.57,P= .011). All patients in the trial received temozolomide as standard-of-care. The primary endpoint of the trial was OS with scondary endpoints being PFS along with other measures.
Limited to 7.5 months post-treatment in the HLA-A2+ group, a response measured using immune criteria to ICT-107 was found to significantly correlate with OS improvement. At this time point, the median OS with ICT-107 was 17.6 versus 13.7 months (P= .0018), with 60% of the ICT-107-treated patients demonstrating a significant immune response compared with 36% of patients in the control arm (P= 0.0084).
Furthermore, levels of IL-12 production were linked with survival. In the limited group, high IL-12 producers had a median OS of 20.6 months compared with 15.4 months for low producers (P= .0515). In the full population of HLA-A2+ responders, those who produced high levels of IL-12 had an extension in OS of 54% versus 31% in IL-12 low producers (P= .0426). In the high group, PFS was extended by 43% versus 19% in the low group (P= .0293).
“The final data from the phase II trial continue to demonstrate the therapeutic value of ICT-107 as a potential treatment for patients with newly diagnosed glioblastoma, and strongly support advancing to phase III testing,” John S. Yu, MD, founder of ImmunoCellular Therapeutics, the manufacturer of ICT-107, said in a statement.
The findings from this study help predict potential results from the larger study for ICT-107, which is composed of autologous dendritic cells incubated with 6 synthetic peptide CTL epitopes that target the GBM/stem cell-associated antigens MAGE-1, HER2, AIM-2, TRP-2, gp100, and IL-13Rα2.
The phase III registration trial will enroll more than 400 HLA-A2+ patients with GBM in approximately 120 sites in the United States, Canada, and the European Union. Patients will be randomized to received temozolomide plus control or ICT-107. The primary endpoint of the trial will be OS and secondary endpoints will be PFS and safety, as well as OS in the two pre-specified MGMT subgroups. The phase III study will employ a different control comprised of the patients’ own monocytes, which are less immunologically active than dendritic cells.
The phase III trial was formed under a special protocol assessment with the FDA, which was granted in August 2015. The study hopes to begin enrolling patients soon. Special protocol assessment is a written agreement between the sponsor company, ImmunoCellular Therapeutics, and the FDA on the design, clinical endpoints, size, and statistical design of a clinical trial. The agreement is intended support findings submitted to the FDA for regulatory filings.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More